Molecular Devices Launches Molecular Devices® SpectraMax® M3 and M4 Multi-Mode Microplate Readers
SpectraMax Line of Readers Now Includes 14 Unique Configurations to Accommodate Wide Range of Customer Detection Needs
SUNNYVALE, CA, December 16, 2009 — Molecular Devices, a leader in innovative solutions for drug discovery and life-sciences research, today announced the launch of the Molecular Devices® SpectraMax® M3 and M4 Multi-Mode Microplate Readers.
These two new systems, which are now commercially available, were designed specifically in response to requests from existing users of SpectraMax® Readers for more affordable multi-mode detection capabilities. By offering two new configurations of multi-mode readers that deliver increased capabilities over the M2/M2e Dual-Mode Readers at a more affordable price than the top-of-the-line M5/M5e Multi-Mode Readers, Molecular Devices can now meet an even greater combination of detection, application, and budgetary needs.
"With the launch of the Molecular Devices® SpectraMax® M3 and M4 Multi-Mode Microplate Readers, we now offer a full range of multi-mode detection capabilities within our SpectraMax® product line," said Andy Boorn, President of Molecular Devices. "With this complete portfolio of multi-mode configurations, we can deliver multi-mode detection into the hands of just about any research scientist who needs the technology. More importantly, we have addressed the needs of our customers for multi-mode readers that fit a variety of budget and application needs."
Furthermore, since research needs change continually as science advances, Molecular Devices designed the M3 and M4 readers as modular systems to ensure users had access to easy upgrade paths. The Molecular Devices® SpectraMax® M3 Reader provides three detection modes: UV-Vis absorbance, fluorescence intensity, and luminescence, but can be upgraded to include time-resolved fluorescence and/or fluorescence polarization modes. The M4 Reader offers the same modes as the M3 Reader, plus time-resolved fluorescence, and can be upgraded to include fluorescence polarization.
Like all SpectraMax® Readers, the new M3 and M4 readers leverage patented technologies to deliver added value to users. The readers are built on a dual-monochromator platform to deliver the convenience of a monochromator-based instrument with sensitivity similar to filter-based platforms. In addition, SpectraMax® Readers enable well-volume detection via the patented PathCheck® Sensor and superior optical capabilities via a patented Smart Optics™ Design.
All SpectraMax® M Series Readers accommodate a cuvette as well as six-well to 384-well standard microplates. All leverage the same industry-leading SoftMax® Pro Data Acquisition and Analysis Software which offers users more than 150 pre-programmed application protocols. In addition, SoftMax® Pro GxP Software helps users adhere to United States Food and Drug Administration (FDA) 21CFR Part 11 compliance requirements. Few other microplate readers offer this combination of flexibility, sensitivity, ease-of-use, and brand value while accommodating almost any combination of detection, application, and budgetary needs.
About SpectraTest® Validation Packages
Molecular Devices also offers companion products to ensure that its microplate readers consistently deliver peak performance to users. With detection mode-specific SpectraTest® Validation Packages, users can validate up to 13 different parameters that affect instrument performance. Pre-programmed protocols within SoftMax® Pro Software handle the validation process, and Molecular Devices offers a recertification program for all SpectraTest® Validation Plates. Further, users who work in regulated industries can easily adhere to requirements by leveraging pre-programmed compliance protocols within SoftMax® Pro GxP Software.
About SpectraMax® Multi-Mode Microplate Readers
SpectraMax® Multi-Mode Microplate Readers offer numerous configurations to make the power of multi-mode detection capabilities fit within almost any budget. SpectraMax® Readers are built on a patented, dual-monochromator detection technology which improves instrument usability while delivering detection capabilities similar to those provided by filter-based readers. As a result, SpectraMax® Readers offer tunability and high-performance detection in a flexible and automatable platform that will support just about any assay or application need—now and into the future. All SpectraMax® Readers come with SoftMax Pro® Software, which offers more than 150 pre-programmed protocols. In addition, users can ensure consistent performance of their readers via a portfolio of validation and compliance tools.
SpectraMax® Microplate Readers are for research use only; not for use in diagnostic procedures.
For more information, please visit www.moleculardevices.com or send an email to info@moldev.com.
Molecular Devices, SpectraMax®, SpectraTest®, SoftMax®, and all other trademarks are the property of Molecular Devices (U.S.) Inc.
About Molecular Devices
Molecular Devices, a business unit of MDS Inc., is focused on the research, design, manufacture and marketing of state-of-the-art tools for mass-spectrometry, drug discovery and bioresearch. Molecular Devices products are designed to help accelerate the complex process of discovering and developing new drug compounds, and are sold to research scientists around the world. The mass-spectrometer product lines are also sold globally through joint ventures with two of the world's leading analytical instrumentation and life-sciences companies, Life Technologies Corporation and PerkinElmer, Inc. Find out more at www.mdssciex.com or www.moleculardevices.com.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS, Inc. has more than 3,600 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
SOURCE: MDS
For further information contact:
Media:
Lisa English
(408) 747-3630
lisa.english@moldev.com
|
